000057786 001__ 57786
000057786 005__ 20200221144222.0
000057786 0247_ $$2doi$$a10.3390/ijms17111861
000057786 0248_ $$2sideral$$a97054
000057786 037__ $$aART-2016-97054
000057786 041__ $$aeng
000057786 100__ $$aLorente, L.
000057786 245__ $$aAssociation between interleukin-6 promoter polymorphism (-174 G/C), serum interleukin-6 levels and mortality in severe septic patients
000057786 260__ $$c2016
000057786 5060_ $$aAccess copy available to the general public$$fUnrestricted
000057786 5203_ $$aThe association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053-0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074-1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days.
000057786 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000057786 590__ $$a3.226$$b2016
000057786 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b54 / 166 = 0.325$$c2016$$dQ2$$eT1
000057786 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b116 / 287 = 0.404$$c2016$$dQ2$$eT2
000057786 592__ $$a1.235$$b2016
000057786 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000057786 593__ $$aPhysical and Theoretical Chemistry$$c2016$$dQ1
000057786 593__ $$aComputer Science Applications$$c2016$$dQ1
000057786 593__ $$aInorganic Chemistry$$c2016$$dQ1
000057786 593__ $$aSpectroscopy$$c2016$$dQ1
000057786 593__ $$aOrganic Chemistry$$c2016$$dQ1
000057786 593__ $$aMolecular Biology$$c2016$$dQ2
000057786 593__ $$aCatalysis$$c2016$$dQ2
000057786 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000057786 700__ $$aMartín, M.M.
000057786 700__ $$aPérez-Cejas, A.
000057786 700__ $$aBarrios, Y.
000057786 700__ $$aSolé-Violán, J.
000057786 700__ $$aFerreres, J.
000057786 700__ $$0(orcid)0000-0002-3312-9383$$aLabarta, L.$$uUniversidad de Zaragoza
000057786 700__ $$aDíaz, C.
000057786 700__ $$aJiménez, A.
000057786 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000057786 773__ $$g17, 11 (2016), 1861 [10 pp]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000057786 8564_ $$s493112$$uhttps://zaguan.unizar.es/record/57786/files/texto_completo.pdf$$yVersión publicada
000057786 8564_ $$s97730$$uhttps://zaguan.unizar.es/record/57786/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000057786 909CO $$ooai:zaguan.unizar.es:57786$$particulos$$pdriver
000057786 951__ $$a2020-02-21-13:15:49
000057786 980__ $$aARTICLE